EQRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 Nov 2023 @ 16:00):

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States...

Stats
Today's Volume	11.93M
Average Volume	2.95M
Market Cap	1.14B
EPS	$-0.180 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.25
ATR14	$0.0660 (2.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-09	Casdin Eli	Sell	5 488 164	Common Stock
2023-11-09	Casdin Eli	Sell	8 110 001	Warrants to purchase Class A Common Stock (right to buy)
2023-11-09	Casdin Eli	Sell	755 766	Earn-out Shares
2023-11-09	Casdin Eli	Sell	101 010	Stock Option (Right to Buy)
2023-11-09	Nallicheri Melanie	Buy	626 999	Common Stock

INSIDER POWER
-96.31
Last 94 transactions
Buy: 76 186 838 \| Sell: 93 441 879

Volume Correlation

Long: 0.04 (neutral)

Short: -0.25 (neutral)

Signal:(55.606) Neutral

EQRx, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

EQRx, Inc. Correlation - Currency/Commodity

0.56
( weak )

0.71
( moderate )

0.00
( neutral )

0.51
( weak )

-0.67
( moderate negative )

EQRx, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.430

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.430

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.205

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.513

Financial Reports:

No articles found.

EQRx, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.